Drug Profile
Research programme: PRS 300 Series - Pieris Pharmaceuticals
Alternative Names: Anticalin®-antibody fusion proteins - Pieris Pharmaceuticals; PRS-300 Series A; PRS-300 Series B & C; PRS-300 Series D; PRS-300sLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Pieris
- Developer Pieris Pharmaceuticals
- Class Antibodies; Antineoplastics; Immunotherapies; Lipocalins
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Aug 2019 Research programme: PRS 300 Series - Pieris Pharmaceuticals is still in preclinical development in Cancer in USA (Pieris pharmaceuticals pipeline August 2019)
- 10 May 2018 Pieris Pharmaceuticals plans to file an IND application for Cancer in 2019